Extracellular vesicles in hematological malignancies: EV-dence for reshaping the tumoral microenvironment
D Van Morckhoven, N Dubois, D Bron… - Frontiers in …, 2023 - frontiersin.org
Following their discovery at the end of the 20th century, extracellular vesicles (EVs) ranging
from 50-1,000 nm have proven to be paramount in the progression of many cancers …
from 50-1,000 nm have proven to be paramount in the progression of many cancers …
[HTML][HTML] Acquisition of drug resistance in endothelial cells by tumor-derived extracellular vesicles and cancer progression
M Morimoto, N Maishi, K Hida - Cancer Drug Resistance, 2024 - ncbi.nlm.nih.gov
Angiogenesis by endothelial cells (ECs) is essential for tumor growth. Angiogenesis
inhibitors are used in combination with anticancer drugs in many tumor types, but tumors …
inhibitors are used in combination with anticancer drugs in many tumor types, but tumors …
PPAR agonists attenuate lenalidomide's anti-myeloma activity in vitro and in vivo
Many patients with multiple myeloma (MM) have comorbidities and are treated with PPAR
agonists. Immunomodulatory agents (IMiDs) are the cornerstones for MM therapy. Currently …
agonists. Immunomodulatory agents (IMiDs) are the cornerstones for MM therapy. Currently …
Extracellular Vesicles in Multiple Myeloma—Cracking the Code to a Better Understanding of the Disease
J Iskrzak, P Zygmunciak, I Misiewicz-Krzemińska… - Cancers, 2022 - mdpi.com
Simple Summary Multiple myeloma is a malignant hematological disease whose
pathomechanism is not yet fully understood on the molecular level. Extracellular vesicles …
pathomechanism is not yet fully understood on the molecular level. Extracellular vesicles …
Lysosomes in Cancer—At the Crossroad of Good and Evil
I Eriksson, K Öllinger - Cells, 2024 - mdpi.com
Although it has been known for decades that lysosomes are central for degradation and
recycling in the cell, their pivotal role as nutrient sensing signaling hubs has recently …
recycling in the cell, their pivotal role as nutrient sensing signaling hubs has recently …
Establishing a prognostic model of ferroptosis-and immune-related signatures in kidney cancer: A study based on TCGA and ICGC databases
Z Han, H Wang, J Long, Y Qiu, XL Xing - Frontiers in Oncology, 2022 - frontiersin.org
Background Kidney cancer (KC) is one of the most challenging cancers due to its delayed
diagnosis and high metastasis rate. The 5-year survival rate of KC patients is less than …
diagnosis and high metastasis rate. The 5-year survival rate of KC patients is less than …
多发性骨髓瘤细胞来源的细胞外囊泡在临床诊疗中的研究进展
徐红佩， 肖淑梅， 王珊， 曹玉林， 陈智超… - 临床血液学杂志, 2024 - lcxy.whuhzzs.com
多发性骨髓瘤(multiple myeloma, MM) 细胞来源的细胞外囊泡(extracellular vesicles, EVs)
通过转运特异性生物活性分子进行细胞间通信, 参与血管生成, 骨溶解, 免疫抑制 …
通过转运特异性生物活性分子进行细胞间通信, 参与血管生成, 骨溶解, 免疫抑制 …
IMiD-Free Interval and IMiDs Sequence: Which Strategy Is Better Suited for Lenalidomide-Refractory Myeloma?
K Suzuki, S Yano - Life, 2023 - mdpi.com
This review discusses immunomodulatory drug (IMiDs) sequencing and IMiD-free interval
strategies for lenalidomide-refractory myeloma. IMiDs and proteasome inhibitors (PIs) …
strategies for lenalidomide-refractory myeloma. IMiDs and proteasome inhibitors (PIs) …
Lenalidomide in multiple myeloma: Review of Resistance Mechanisms, current treatment strategies and future perspectives
P Kulig, S Milczarek, E Bakinowska, L Szalewska… - Cancers, 2023 - mdpi.com
Simple Summary Multiple myeloma (MM) is the second most common hematological
malignancy. Initially, prognosis for MM patients was poor. However, due to the development …
malignancy. Initially, prognosis for MM patients was poor. However, due to the development …
[HTML][HTML] Aberrant regulation of serine metabolism drives extracellular vesicle release and cancer progression
Cancer cells secrete extracellular vesicles (EVs) to regulate cells in the tumor
microenvironment to benefit their own growth and survive in the patient's body. Although …
microenvironment to benefit their own growth and survive in the patient's body. Although …